Floatz logo

Solu-Cortef

Congenital Adrenal Hyperplasia

University of Texas Southwestern Medical CenterPhase 4 / ApprovedActive
A
81/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
72/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Congenital Adrenal Hyperplasia cohort.

Asset / SponsorPhaseRating
Cortisone
Federico II University
Phase 4BBB
Atumelnant
Crinetics Pharmaceuticals Inc.
Phase 3BB
FLUDROCORTISONE
University of Texas Southwestern Medical Center
Phase 3BB
DEXAMETHASONE
Shanghai Jiao Tong University School of Medicine
Phase 4BB
Crinecerfont
Neurocrine Biosciences
Phase 3BB

View all 21 →

Same molecule, other indications

Solu-Cortef is also rated in:

myelodysplastic syndromeDormant
BB
Indicative ·
68 / 100
View asset →
childhood acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
adrenocortical insufficiencyDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →